We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Boston Scientific

Boston Scientific is a biomedical/biotechnology engineering company and multinational manufacturer of medical devices... read more Featured Products: More products

Download Mobile App




Next-Gen Insertable Cardiac Monitor Offers Long-Term Monitoring for Arrhythmias

By HospiMedica International staff writers
Posted on 04 Oct 2023

A next-generation insertable cardiac monitor (ICM) uses enhanced detection algorithms for long-term monitoring of arrhythmias associated with conditions like atrial fibrillation (AF), cryptogenic stroke, and syncope. More...

Boston Scientific (Marlborough, MA, USA) has launched the LUX-Dx II+ ICM System which features two-stage algorithms to first identify and then confirm potential arrhythmias before sending an alert to healthcare providers. This ensures that the data clinicians receive is both reliable and useful for making treatment decisions. What's more, the device offers remote programming, allowing doctors and healthcare teams to modify detection settings and track symptoms without requiring a face-to-face consultation with the patient.

The dual-stage algorithms in the LUX-Dx II+ ICM System can be configured to spot various types of heart irregularities such as AF, atrial and ventricular tachycardia, bradycardia, and episodes of rhythm pause. These algorithms include a newly added feature for premature ventricular contraction (PVC) burden, designed to recognize arrhythmias whenever preset limits or guidelines are surpassed. The system also employs additional verification filters, including specific settings for nighttime that focus on bradycardia and pause incidents, aiming to eliminate false positives and irrelevant episodes. For enhanced patient experience, the system also offers a new app for easier and more streamlined remote monitoring.

“The LUX-Dx II+ ICM System builds on a strong foundation of cardiac diagnostic technologies at Boston Scientific to provide care teams with the necessary data for critical decision making,” said Scott Olson, senior vice president and president, Cardiac Rhythm Management and Diagnostics, Boston Scientific. “With enhanced and new diagnostic algorithms, physicians will receive timely, accurate and actionable insights to help them make clinically meaningful decisions.”

Related Links:
Boston Scientific


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Powered Surgical Stapler
ECHELON 3000 Stapler
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.